About GlycoMar
Management
Dr Charlie Bavington, Managing Director.
Founder of GlycoMar. He is a biochemist with over 8 years experience in marine biotechnology. A graduate of the University of Edinburgh, he completed his Ph.D. at the same university, studying proteoglycan metabolism in cartilage.
This was followed by postdoctoral research at Dunstaffnage marine lab studying invertebrate glycans and cell adhesion. Subsequently he worked for Integrin Advanced Biosystems Ltd, a marine biotechnology and testing company, holding the positions of Operations Manager and Research & Development Manager. His scientific interest is in glycobiology and its role in cell-cell interactions.
View Charlie’s linkedin profile
Dr Mike Wyllie, Chairman & Non-executive director.
Dr Mike Wyllie, Director and Founder of Global Pharma Consulting Limited (GPC Ltd). He has over 25 years of experience in senior management level positions within the pharmaceutical industry including Wyeth and Pfizer. He co-founded Plethora Solutions Ltd. in 2003 which was successfully listed on the London Stock Exchange in March 2005 (AIM: PLE). He is also a non-executive director and CSO of the medical technology company, Zi Medical Plc, a non executive director of Taihua Plc and an executive director of Bactomed Limited.
Mr Brad Hoy, Non-executive director, CFO.
Mr Brad Hoy, Director and co-founder of Seven Hills Venture Partners and non-executive Director of e-Therapeutics plc. Brad is a Chartered Management Accountant with over 15 years of commercial experience in the pharmaceutical and biotechnology industries through financial and general management roles in the UK and the USA. Previously Brad was Chief Financial Officer of Plethora Solutions Holdings plc, an AIM-listed pharmaceutical company, Chief Executive Officer of Xcellsyz Ltd, a UK venture capital-backed life science company and Senior Director of Geron Corporation’s stem cell-focused UK subsidiary. Prior to co-founding Seven Hills, Brad was Chief Financial Officer at Cyclacel Ltd, a UK oncology company and held senior financial management positions at ChiRex Inc, a US-based pharmaceutical CMO.
Scientific Advisory Board
Professor Marcel Jaspars
Professor of organic chemistry at the University of Aberdeen. Research in the Jaspars group focuses on the functions and applications of natural products, particularly those from marine invertebrates. The goal of the work is to determine the biological role of selected natural products as well as using others as pharmaceuticals, tools for biomedical research, fluorosensors and catalysts. The main themes of his research are the functions and applications of natural products, particularly those from marine organisms. This encompasses two broad areas, the use of marine natural products as potential pharmaceuticals and tools for biomedical research and the interactions of these metabolites with transition metals.
Dr. Bob Lauder
Lecturer in Biochemistry at the University of Lanacaster. He has extensive glycobiology expertise through his research concerned with the structure and function of proteoglycans and glycosaminoglycans.
Prof. Gerard Nash
Professor of Cardiovascular Rheology in the Division of Medical Sciences in the Medical School at the University of Birmingham. Past-president of the International Society for Biorheolgy. Expert in the mechanical properties of blood cells which affect their circulation, and in modelling the processes which influence the recruitment of leukocytes from the circulation into tissue. Main research interest in the regulation of protective vascular inflammatory responses by the local physico-chemical environment, and how disruption of this finely tuned response leads to pathology.